The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience.

Saved in:
Bibliographic Details
Title: The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience.
Authors: Sim, V.1 (AUTHOR), Forner, S.1 (AUTHOR), Burcombe, R.1 (AUTHOR), Glendenning, J.1 (AUTHOR)
Source: Clinical Oncology. Jul2019, Vol. 31 Issue 7, pe114-e114. 1p.
Database: Academic Search Ultimate
Description
ISSN:09366555
DOI:10.1016/j.clon.2019.03.034